Aldar S. Bourinbaiar

Awards Nomination 20+ Million Readerbase

PMC/PubMed Indexed Articles

Maintenance and Intensification of Bivalent Oral Poliovirus Vaccine Use Prior to its Coordinated Global Cessation

MEFA (multiepitope fusion antigen)-Novel Technology for Structural Vaccinology, Proof from Computational and Empirical Immunogenicity Characterization of an Enterotoxigenic Escherichia coli (ETEC) Adhesin MEFA

Google Scholar citation report

Citations : 2341

Journal of Vaccines & Vaccination received 2341 citations as per Google Scholar report

Journal of Vaccines & Vaccination peer review process verified at publons

25+ Million Website Visitors

Indexed In

Academic Journals Database
Open J Gate
Genamics JournalSeek
JournalTOCs
China National Knowledge Infrastructure (CNKI)
Scimago
Ulrich's Periodicals Directory
RefSeek
Hamdard University
EBSCO A-Z
OCLC- WorldCat
Publons
MIAR
University Grants Commission
Geneva Foundation for Medical Education and Research
Euro Pub
Google Scholar

Useful Links

Share This Page

Tweets by Vaccine41931315

Open Access Journals

Aldar S. Bourinbaiar

Aldar S. Bourinbaiar

Jan Comenius University, Bratislava, Czechoslovakia, Duke university, USA

Biography

Dr. Aldar S. Bourinbaiar is CEO of Immunator, Canada. He received his PhD from Université de la Sorbonne - Université de Paris. Dr. Aldar S. Bourinbaiar has over 20 peer reviewed publications and is funded by the NIH, VA , NSF and several foundations. Dr. Aldar S. Bourinbaiar research interests include vaccines, immunotherapy, infectious diseases, cancer, atherosclerosis